ClinicalTrials.gg
RecruitingNCT05648292SELFSEPUpdated Sep 6, 2023

The Relationships Between Personal Identity, Autobiographical Memory and Future Thinking in People With Multiple Sclerosis

An observational study in Multiple Sclerosis, Relapsing-Remitting and Healthy Controls, sponsored by Centre d'Investigation Clinique et Technologique 805. Recruiting at 1 site in France. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-06.

Sponsored by Centre d'Investigation Clinique et Technologique 805 · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
90
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France — 9 open to participants now, 14 under way, 7 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · France.

Planned enrollment
11th of 12
90 · median 499
Started
2022
with 2 others
Observational
12 of 82
1 open now
Primary completion
2024-12
later than 0 of 13 live
Registered
72nd of 82
by date

Among the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, this one is the 11th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2022, is one of 12 observational ones, reaches primary completion later than 0 of the 13 other live ones, and was the 72nd registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

9 of the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, or all of them as a file.
02

Study summary

Personal identity is composed of multiple facets of the self that are constructed and nourished through memories of past experiences (i.e., autobiographical memory) and the imagination of events that may occur in the future (i.e., future thinking) .

While our previous work has shown that people with relapsing-remitting multiple sclerosis (pwRRMS) have autobiographical memory and future thought disorders, their impact on personal identity has not yet been explored. Based on a cognitive and clinical neuropsychology approach, this research project aims to better understand the cognitive mechanisms involved in the relationship between identity, autobiographical memory and future thinking in pwRRMS. We will examine the extent to which pwRRMS manage to maintain and reshape their identity through life experiences, with a particular interest in the potential integration of the disease as a facet of their identity. In addition, we will explore the positive and/or negative consequences of disease-related identity changes on emotional well-being and quality of life, as well as their links with the duration and severity of the disease. Overall, this research project will contribute to identify new therapeutic levers that can be used for the development of adapted and personalized care.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting
  • Healthy Controls
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Primary care clinic

Eligibility criteria

For the clinical group:

Inclusion Criteria:

  • Diagnosis of relapsing-remitting MS according to the McDonald's revised diagnostic criteria
  • People aged between 18 and 55
  • French native speaker
  • Access to a computer or tablet, equipped with internet access, a camera and a microphone

Non-inclusion Criteria:

  • MS relapse in the month prior to the inclusion
  • Treatment with during the month preceding the inclusion
  • Form of MS other than the relapsing-remitting form
  • Neurological history (other than MS for patients), history or current presence of psychiatric disorders (e.g., depression, anxiety disorders, schizophrenia), substance abuse (e.g., alcohol, cannabis; past or present)
  • Other diagnosed chronic pathology(ies) (other than MS for patients)
  • Severe cognitive impairment
  • Persons mentioned in Articles L1121-6 to L1121-8 in the French law (minors, persons deprived of liberty, adults subject to protective measures)

For the control group:

Inclusion Criteria:

  • People aged between 18 and 55
  • Matched in age, gender and level in education
  • French native speaker
  • Access to a computer or tablet, equipped with internet access, a camera and a microphone

Non-inclusion Criteria:

  • Neurological history (other than MS for patients), history or current presence of psychiatric disorders (e.g., depression, anxiety disorders, schizophrenia), substance abuse (e.g., alcohol, cannabis; past or present)
  • Other diagnosed chronic pathology(ies) (other than MS for patients)
  • Severe cognitive impairment
  • Persons mentioned in Articles L1121-6 to L1121-8 in the French law (minors, persons deprived of liberty, adults subject to protective measures)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
90 participants (estimated)
Target follow-up
15 Days
Patient registry
Yes

Groups and cohorts

  • Clinical group

    45 individuals with relapsing-remitting multiple sclerosis

    Behavioral: Neuropsychological tests and psychological questionnaires

  • Control group

    45 individuals with no chronic disease, matched in age, gender and level of education

    Behavioral: Neuropsychological tests and psychological questionnaires

Interventions

  • BehavioralNeuropsychological tests and psychological questionnaires

    * The clinical group will complete: * the BCcogSEP: a comprehensive neuropsychological examination * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression * The control group will complete: * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression

06

What researchers measure

Primary outcomes

  1. Relationships between personal identity, autobiographical memory and future thinking

    Scores obtained at the I AM and I WILL BE tasks assessing the access, qualitative properties of self-concepts, episodic richness and temporal organization of past and future events around self-concepts (between-group comparisons, pwRRMS versus control group)

    Time frame: 15 days

Secondary outcomes

  1. Relationships between personal identity, psychological functioning and clinical characteristics

    Correlations between IAM and I WILL BE scores and scores obtained at the different questionnaires (BRIEF COPE, Connor Davidson Resilience Scale, Satisfaction with Life Scale, Hospital Anxiety and Depression Scale) Correlations between IAM and I WILL BE scores and level of functional disability (Expanded Disability Status Scale) Correlations between IAM and I WILL BE scores and disease duration

    Time frame: 15 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2024, 24 months after the start.

Of 42 non-industry observational studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 56. This study's planned 24 months is below that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 22 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2022
First posted
Dec 13, 2022
StartActual
Dec 7, 2022
Primary completionEst.
Dec 7, 2024
CompletionEst.
Jun 7, 2025
Last update
Sep 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05648292
Lead sponsor
Centre d'Investigation Clinique et Technologique 805
Collaborators
University Paris 8 Vincennes Saint Denis, ARSEP foundation
Responsible party
Alexandra Ernst (Associate Professor, Centre d'Investigation Clinique et Technologique 805) — Principal investigator
First posted
Dec 13, 2022
Start date
Dec 7, 2022
Primary completion
Dec 7, 2024 (estimated)
Completion
Jun 7, 2025 (estimated)
Last update
Sep 6, 2023

Study contacts

Alexandra Ernst, PhD
Contact
aernst@univ-paris8.fr
+33628496210
Alexandra ERNST, PhD
principal investigator · Laboratoire DysCo - Université Paris 8

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion